Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q3 2025 · 10-Q
Revenue$86.00K$86.00K— vs Q3 2024 Net Income-$19.39M-$19.39MN/M vs Q3 2024 EPS, diluted—
Operating Income-$20,367,000N/M Operating Cash Flowderived-$13,039,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,101,000N/M Margins · derivedOperating margin-23682.6%
Net margin-22540.7%
ended Sep 30, 2025 · filed Nov 5, 2025 · 36 d after period end